AgomAb Therapeutics NV (NASDAQ:AGMB – Get Free Report) Director David Epstein bought 5,000 shares of AgomAb Therapeutics stock in a transaction that occurred on Tuesday, November 17th. The shares were bought at an average cost of $5.57 per share, with a total value of $27,850.00. Following the acquisition, the director directly owned 59,980 shares in the company, valued at $334,088.60. This trade represents a 9.09% increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website.
AgomAb Therapeutics Stock Performance
NASDAQ AGMB opened at $5.82 on Thursday. AgomAb Therapeutics NV has a twelve month low of $5.50 and a twelve month high of $17.82. The stock has a fifty day simple moving average of $9.02 and a 200 day simple moving average of $11.63.
Analyst Upgrades and Downgrades
A number of research analysts recently issued reports on AGMB shares. Piper Sandler assumed coverage on shares of AgomAb Therapeutics in a research report on Tuesday, August 25th. They set an “overweight” rating and a $60.00 price target for the company. B. Riley Financial started coverage on shares of AgomAb Therapeutics in a report on Thursday, July 23rd. They set a “buy” rating and a $34.00 price objective on the stock. Wall Street Zen downgraded AgomAb Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, September 27th. HC Wainwright reiterated a “buy” rating on shares of AgomAb Therapeutics in a report on Wednesday, October 21st. Finally, Johnson Rice restated a “buy” rating on shares of AgomAb Therapeutics in a research note on Wednesday, October 21st. Eight equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $37.50.
Check Out Our Latest Report on AGMB
AgomAb Therapeutics Company Profile
Agomab Therapeutics is a clinical-stage biopharmaceutical company developing medicines for fibrotic and inflammatory diseases. Its research focuses on growth-factor pathways involved in tissue repair and fibrosis. The company’s pipeline includes AGMB-129, an oral, gut-restricted inhibitor of the TGF-? receptor ALK5 being developed for fibrostenotic Crohn’s disease, and AGMB-447, an inhaled therapy targeting integrins for fibrotic lung disease. Agomab is also developing antibody-based approaches to fibrosis.
Featured Stories
- Five stocks we like better than AgomAb Therapeutics
- From Berlin to Brussels: Tesla’s $3.3 Billion Robotaxi Gamble
- Target Stock Is Up Over 70%—Has the Easy Money Already Been Made?
- Amazon’s Zoox Just Joined Uber—Could That Change the Robotaxi Threat?
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
Receive News & Ratings for AgomAb Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AgomAb Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
